Association of type III collagen turnover with cardiovascular outcomes and impact with canagliflozin in the CANVAS Program: A post hoc analysis
Authors' conclusion
The changes in PRO-C3 and CTX-III reflect a shift in the dynamics of COL3 turnover following treatment with canagliflozin. These biomarkers are promising pharmacodynamic tools that can be used to monitor the impact of canagliflozin treatment and possibly other sodium-glucose co-transporter-2 inhibitors on tissue remodelling in future interventional trials.
Study context
- Population
- Participants with T2D in the CANVAS Program biomarker substudy
- Comparison
- Canagliflozin vs placebo
Primary result
As reported in the abstract
COL III turnover biomarkers (PRO-C3, C3M, CTX-III) and clinical outcomes (HF hospitalization, CV death, all-cause mortality) · baseline and year 3
- Higher baseline PRO-C3 and C3M associated with increased incidence of all investigated outcomes
- Baseline CTX-III not associated with any investigated outcome
- PRO-C3 decreased and CTX-III increased following canagliflozin treatment
- Increase in PRO-C3 from baseline to year 3 in placebo arm associated with increased incidence of CV outcomes
- Increase in PRO-C3 from baseline to year 3 in all participants associated with increased risk of all-cause mortality
Original publication
Association of type III collagen turnover with cardiovascular outcomes and impact with canagliflozin in the CANVAS Program: A post hoc analysis. Diabetes Obes Metab. Published 16 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →